Zoltan Vajo

Zoltan Vajo is a Hungarian/American scientist, best known [1] for his contributions to the Human Genome Project, including cloning the COQ7 gene,[2] characterizing the human CLK-1 timing protein cDNA [3] and its potential effect on aging,[4] and research on the molecular and genetic background of skeletal dysplasias and fibroblast growth factor receptor 3 disorders, including Achondroplasia, SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans), Thanatophoric dysplasia, Muenke coronal craniosynostosis and Crouzon syndrome [5] as well as more recently on genetically engineered insulin analog molecules, including their structure, metabolic effects and cellular processing [6] and the role of recombinant DNA technology in the treatment of diabetes [7] .

Vajo et al. in 1999 cloned COQ7 from human heart. They found that the predicted protein contains 179 amino acids, is mostly helical, and contains an alpha-helical membrane insertion. It has a potential N-glycosylation site, a phosphorylation site for protein kinase C and another for casein kinase II, and 3 N-myristoylation sites. Northern blot analysis detected 3 transcripts; a 1-kb transcript was predominant in heart, and a 3-kb transcript was predominant in skeletal muscle, kidney, and pancreas.[8]

Vajo et al. found in 2000 that alterations in venous reactivity to alpha- and beta-adrenergic, nitric oxide (NO)-dependent, and other drugs are present in many genetically determined and acquired conditions, such as hypertension, smoking, and aging.[9]

In 2001, Fawcett, Bennett, Hamel, Vajo and Duckworth showed that the effect of insulin and its analogues on protein degradation vary significantly in different cell types and with different experimental conditions. The differences seen in the action of the insulin analogues cannot be attributed to binding differences only. Post-receptor mechanisms, including intracellular processing and degradation, must be also considered.[10]

More recently (2007-2010), Vajo et al. developed novel influenza vaccines based on reverse genetics technology, including vaccines against the H5N1 bird flu and the H1N1 swine flu viruses, as well as seasonal influenza. [11] In preparation for the influenza pandemic, Vajo and Jankovics showed that instead of the conventionally used split virion or subunit vaccines, lower doses of whole virus vaccines are able to induce sufficient immune responses even against newly emerged influenza virus strains in pediatric [12] adult and elderly patients, without increasing the rate of adverse events.[13] This was achieved in part by using aluminum phosphate as an adjuvant.

Selected publications

In the media

On CNN, July 29, 2007

The Doctors' Channel, December 23, 2008

The Daily Miner, April 16, 2010

The Daily Miner, July 12, 2010

References

  1. ^ OMIM - Online Mendelian Inheritance in Man. ID 601683. http://www.ncbi.nlm.nih.gov/omim/601683
  2. ^ NCBI - National Center for Biotechnology and Information http://www.ncbi.nlm.nih.gov/nuccore/AF053770.1
  3. ^ NCBI - National Center for Biotechnology and Information http://www.ncbi.nlm.nih.gov/nuccore/AF032900.1
  4. ^ Rustin P, Von Kleist-Retzow, J.-C, Vajo Z, Rotig A, Munnich A. (April 2000). "For debate: defective mitochondria, free radicals, cell death, aging-reality or myth-ochondria?". Mechanisms of Ageing and Development 114 (3): 201–206. doi:10.1016/S0047-6374(00)00102-0. PMID 10802124. 
  5. ^ Vajo Z, Francomano CA, Wilkin DJ (February 2000). "The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans". Endocrine Reviews 21 (1): 23–39. doi:10.1210/er.21.1.23. PMID 10696568. 
  6. ^ Vajo Z, Duckworth W. (March 2000). "Genetically engineered insulin analogs: Diabetes in the new millenium". Pharmacological Reviews 52 (1): 1–9. PMID 10699152. 
  7. ^ Vajo Z, Fawcet J, Duckworth W. (October 2001). "Recombinant DNA technology in the treatment of diabetes: insulin analogs.". Endocrine Reviews 22 (5): 706–17. doi:10.1210/er.22.5.706. PMID 11588149. 
  8. ^ Vajo Z, King LM, Jonassen T, et al. (October 1999). "Conservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for aging". Mammalian Genome 10 (10): 1000–4. doi:10.1007/s003359901147. PMID 10501970. 
  9. ^ Vajo Z, Dachman W, Szekacs B (May 2000). "Alterations of venous drug reactivity in humans: acquired and genetic factors.". Angiology 51 (5): 361–6. doi:10.1177/000331970005100502. PMID 10826852. 
  10. ^ Fawcett J, Hamel FG, Bennett RG, Vajo Z, Duckworth WC. (April 2001). "Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity". Journal of Biological Chemistry 276 (15): 11552–8. doi:10.1074/jbc.M007988200. PMID 11116143. 
  11. ^ Vajo Z, Wood J, Kosa L, Szilvasy I, Paragh G, Pauliny Z, Bartha K, Visontay I, Kis A, Jankovics I. (February 2010). "A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development.". J Virol. 84 (3): 1237–42. doi:10.1128/JVI.01894-09. PMID 19906909. 
  12. ^ Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Kis A, Tarjan I, Rozsa N, Jankovics I. (December 2008). "Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.". Pediatric Infectious Disease Journal 27 (12): 1052–6. doi:10.1097/INF.0b013e3181861dd7. PMID 18978514. ,
  13. ^ Vajo Z, Tamas F, Sinka L, Jankovics I. (January 2010). "Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial". Lancet 375 (9748): 49–55. doi:10.1016/S0140-6736(09)62039-0. PMID 20018367.